Robeco Schweiz AG Has $7.02 Million Position in CVS Health Corporation $CVS

Robeco Schweiz AG lessened its position in CVS Health Corporation (NYSE:CVS) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 93,074 shares of the pharmacy operator’s stock after selling 9,508 shares during the quarter. Robeco Schweiz AG’s holdings in CVS Health were worth $7,017,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in CVS. Vanguard Group Inc. boosted its holdings in CVS Health by 1.7% during the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares during the last quarter. State Street Corp grew its holdings in shares of CVS Health by 1.4% in the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after acquiring an additional 800,414 shares in the last quarter. Geode Capital Management LLC increased its position in shares of CVS Health by 2.4% in the second quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock valued at $1,966,083,000 after acquiring an additional 675,824 shares during the last quarter. Invesco Ltd. raised its holdings in CVS Health by 15.3% during the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after acquiring an additional 3,118,626 shares in the last quarter. Finally, Norges Bank acquired a new position in CVS Health during the second quarter valued at approximately $1,358,698,000. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Performance

CVS opened at $80.63 on Wednesday. The firm has a market cap of $102.36 billion, a P/E ratio of 212.20, a price-to-earnings-growth ratio of 0.74 and a beta of 0.48. The business’s fifty day moving average is $78.78 and its 200-day moving average is $74.10. CVS Health Corporation has a 52-week low of $50.14 and a 52-week high of $85.15. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date is Thursday, January 22nd. CVS Health’s payout ratio is currently 700.00%.

Analysts Set New Price Targets

Several research firms have recently commented on CVS. TD Cowen increased their price objective on CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. Leerink Partners raised their price objective on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Barclays increased their price target on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Morgan Stanley raised their price objective on shares of CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.86.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein raised its price target to $91 and reaffirmed a Market Perform rating, signaling incremental analyst support for a higher valuation and helping sentiment on the name. Bernstein raises PT on CVS Health (CVS) to $91, reiterates ‘market perform’ rating
• Positive Sentiment: Gilead said its new HIV prevention shot has been added to CVS’s drug coverage lists for commercial plans — a win for pharmacy and PBM revenue mix and utilization that could lift prescription volume and margins. Gilead’s new HIV prevention shot added to CVS’s drug coverage lists, CEO says
• Positive Sentiment: High-profile media commentary (Jim Cramer) highlighting CEO Karen Lynch/management execution (“Joyner’s money”) is boosting investor confidence in leadership and strategy. Jim Cramer on CVS CEO: “Joyner’s Money”
• Neutral Sentiment: Research outlets (Zacks) are publishing favorable screens on CVS as a top-ranked value and momentum stock and highlighting strong earnings surprise history — these pieces raise investor attention but are informational unless followed by concrete catalyst. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Neutral Sentiment: Zacks coverage also notes heavy investor searches and discusses the company’s likelihood of beating upcoming estimates — increased attention can boost liquidity and short-term momentum but isn’t a direct fundamental change. Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
• Negative Sentiment: An Illinois risk pool has sued Eli Lilly, CVS and UnitedHealth over insulin pricing — this litigation adds regulatory and legal risk, potential damages and reputational downside that could pressure the stock if claims escalate or lead to material fines. Illinois risk pool sues Eli Lilly, CVS, UnitedHealth over insulin pricing

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.